United States 
Canada (EN) 
México 
France 
Deutschland 
United Kingdom 
Immon Shafiei focuses his practice on representing employers in labor and employment matters in a wide variety of issues, including litigation involving discrimination, wage and hour issues, retaliation, harassment, and ADA claims before state and federal courts and administrative agencies. Immon is involved in all areas of case management and phases of litigation, including drafting pleadings, responding to discovery, preparing motions, preparing witnesses for depositions and trial testimony, and defending his client’s interests during trial. Immon also counsels his clients throughout the litigation process to ensure that his client’s objectives and values are met.
Immon is a member of the firm’s Workplace Investigations and Organizational Assessments Practice Group. He leads internal investigations of critical, and often sensitive and high profile, issues for firm clients. These include investigations of complex matters involving claims of pattern/practice discrimination, systemic inequity in workplace practices, executive misconduct, sexual assault, and unconscious bias. Immon has assisted clients in various industries with organizational and cultural impact assessments, mitigating brand-altering crisis, and developing strategic action plans based on investigative findings. He also trains HR personnel on best practices for handling investigations. Immon’s experience includes:
- Investigating allegations of systemic discrimination and mistreatment of people of color and/or with mental health disabilities, including pay and promotional inequity, at a global information company
- Investigating allegations of fraud and financial misconduct at a regional manufacturing company
- Investigating concerns regarding alleged misconduct and third party use of company platform to share improper and inappropriate sexually explicit communications
- Investigating allegations of workplace bullying and discriminatory hiring practices based on perceived “diversity initiatives” at a global pharmaceutical company
